Skip to main content
Premium Trial:

Request an Annual Quote

Advanced Biological Laboratories Gets CE-IVD Mark for HIV Genotyping Assays

NEW YORK — Advanced Biological Laboratories said on Tuesday that it has received CE-IVD marking for its DeepChek sequencing-based assays for HIV genotyping and drug resistance testing.

According to Luxembourg-based ABL, the DeepChek-HIV assays cover the protease/reverse transcriptase and the integrase regions of the virus, respectively, and are intended for use with input RNA extracted from plasma, serum, or whole blood samples.

They are designed for settings running either Sanger sequencing or next-generation sequencing workflows and have been validated with ABL's DeepChek library preparation assays on several of Illumina's NGS platforms including the iSeq 100 instrument, the company added.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.